Dr Graeme Wald


BSc(Hons), PhD, MBA, GAICD


Graeme Wald - Principal at OneVentures, leading Australian Venture Capital firm

Deal lead

Prota Therapeutics


Melbourne, AU


Gravitas Consulting & Investments Pty Ltd

Current board roles

Prota Therapeutics (Chair)


Nexvet Biopharma | Saluda Pty Ltd. (alternate director)


Graeme has spent close to 25 years in financial markets as an equities analyst, fund manager and venture capitalist. He headed the Life Science research team at Wilson HTM and played a leading role in numerous IPOS’s and secondary raisings worth more than $750M.

Whilst at Wilson HTM, as head of Life Science Research, Graeme was rated top analyst in the pharmaceutical sector as measured by Starmine against recommendations and investor returns.

As non-executive director of Nexvet Biopharma he was chairman of the Audit and Risk committee and assisted in guiding the company to a NASDAQ listing.

Graeme is originally from South Africa. Whilst at Merill Lynch he was rated top analyst in the Pharmaceutical and Healthcare sector. He was also a member of the top rated Global Paper and Pulp Research team.

Graeme has a broad range of sector experience. He has covered sectors including Life Sciences, pharmaceuticals, health care, transport, and paper and pulp. He also has experience in setting general industrial investment strategies.

Graeme has worked in Israel, America and South Africa as a research chemist in the industrial and energy sectors.

He holds a PhD in chemistry and an MBA from the University of the Witwatersrand.